Biotech RadarJobs updated

COMPANY

Akero Therapeutics

HQ: South San Francisco, CA source · akerotx.com ↗

Status: Acquired, now part of Novo Nordisk · How status works

Clinical Phase 3

1 open job · last seen Oct 23, 2026 · 7 sources

Keywords: metabolic metabolic dysfunction-associated steatohepatitis metabolic diseases NASH - Nonalcoholic Steatohepatitis NASH With Fibrosis MASH With Fibrosis MASH - Metabolic Dysfunction-Associated Steatohepatitis NASH/MASH NAFLD/MASLD Efruxifermin

Location: South San Francisco, CA (US office) · source · Oct 12, 2026

Profile checked Oct 10, 2026

1Open jobs6Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Director - Clinical Development (Medical Monitoring)RemoteAug 20, 2026Oct 9, 2026

See all 1 job

Timeline

  1. Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
  2. Trial start Phase 3: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH source ↗
  3. Trial start Phase 3: A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis source ↗
  4. Trial start Phase 3: A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Li source ↗
  5. Trial start Phase 2: A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) source ↗
  6. Trial start Phase 2: A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) source ↗
  7. Trial start Phase 2: A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Director - Clinical Development (Medical Monitoring)RemoteAug 20, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06215716A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisPhase 3RecruitingDec 1, 20232033-02 (estimated)
NCT06528314A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPhase 3RecruitingSep 4, 20242030-02 (estimated)
NCT05039450A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)Phase 2CompletedJul 30, 2021Dec 15, 2023 (actual)
NCT06161571A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Phase 3Active, not recruitingNov 10, 2023Mar 3, 2026 (actual)
NCT04767529A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)Phase 2CompletedFeb 16, 2021May 2, 2024 (actual)
NCT03976401A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)Phase 2CompletedMay 28, 2019Feb 10, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Akero Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback